User Tools

Site Tools


research:angioedema

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
research:angioedema [2016/12/13 17:20]
jduke
research:angioedema [2017/12/14 05:54] (current)
schuemie
Line 7: Line 7:
 **Rationale:​** The Food and Drug Administration (FDA) has [[http://​www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Surveillance/​AdverseDrugEffects/​ucm491645.htm|recently announced]] that they are evaluating the need for regulatory action regarding a potential association between exposure to the anti-seizure drug Keppra and angioedema. OHDSI seeks to support evidence generation for questions of importance to FDA and other stakeholders seeking to protect and promote the public'​s health. **Rationale:​** The Food and Drug Administration (FDA) has [[http://​www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Surveillance/​AdverseDrugEffects/​ucm491645.htm|recently announced]] that they are evaluating the need for regulatory action regarding a potential association between exposure to the anti-seizure drug Keppra and angioedema. OHDSI seeks to support evidence generation for questions of importance to FDA and other stakeholders seeking to protect and promote the public'​s health.
  
-**Project Lead(s):** Jon Duke, Patrick Ryan, Marc Suchard, Martijn Schuemie+**Project Lead(s):** Jon Duke, Patrick Ryan, Marc Suchard, George Hripcsak, [?Adler], Christian Reich, Yuriy Khoma, Marie-Sophie Schwalm, Yonghui Hu, [Stanford- Juan?], Martijn Schuemie.
  
-**Coordinating Institution(s):​** Regenstrief Institute+**Coordinating Institution(s):​** Regenstrief Institute ​/ Georgia Tech
  
-** Additional Participants ​(currently seeking additional collaborators):**  +**Participating Institution(s):​**  ​Regenstrief Institute, Georgia Tech, Janssen Research ​and Development,​ Columbia University, University of California Los Angeles, University of Texas Houston, Stanford University, QuintilesIMS.
-  * George Hripcsak +
-  +
-Any interested collaborators please contact Jon Duke at jonduke@regenstrief.org ​and I will be happy to add you to the collaborator list+
  
-**Participating Institution(s):​** Regenstrief Institute, Janssen Research and Development,​ Columbia University, University of California, Los Angeles +**Full Protocol:** [[https://github.com/OHDSI/StudyProtocols/blob/master/​KeppraAngioedema/​extras/​KeppraandAngioedemaRiskStudyProtocolv0.5.docx?raw=true|Keppra and Angioedema Risk Protocol]]
- +
-**Full Protocol:** [[https://drive.google.com/file/d/0BzotZ5gIRvegT3Y5djBOUldzaVE/view?usp=sharing|Keppra and Angioedema Risk Protocol]]+
  
 **Initial Proposal Date:​** ​ 5/3/2016 **Initial Proposal Date:​** ​ 5/3/2016
research/angioedema.1481649610.txt.gz · Last modified: 2016/12/13 17:20 by jduke